Impact of a killed Tritrichomonas foetus vaccine on clearance of the organism and subsequent fertility of heifers following experimental inoculation

Edmondson, Misty A.; Joiner, Kellye S.; Spencer, Jennifer; Riddell, K.P.; Rodning, Soren P.; Gard, J. A.; Givens, M. Daniel

doi:10.1016/j.theriogenology.2016.09.056

Cited by 17 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In spite of these challenges, some antiparasitic vaccines have been developed successfully. Boehringer Ingelheim markets a vaccine against cattle trichomoniosis in the USA (TrichGuard®) [79] with annual sales of approximately €1.7 million, as well as Pirodog® [80,81] in some European countries, a killed vaccine against canine babesiosis with annual sales of €5 million. Leishmania vaccines are commercially available, although they offer only limited protection and are often not well tolerated [74,75].…”

Section: Approaches To Antiparasitic Developmentmentioning

confidence: 99%

Antiparasitics in Animal Health: Quo Vadis?

Selzer

Epe

2021

Trends in Parasitology

View full text Add to dashboard Cite

Antiparasitics acting on endo-or ectoparasites represent the second largest segment of the global animal health market, accounting for 23% of market share. However, relatively few novel antiparasitic agents have been introduced into the market during recent decades. One exception, and a groundbreaking 21st century success story, are the isoxazolines, whose full potential has not yet been entirely explored. Unfortunately, resistance issues are present across most parasitic diseases, which generates a clear market need for novel resistance-breaking antiparasitics with new modes/mechanisms of action. Recent advances in science and technologies strongly suggest that the time is right to invest in new modalities such as parasitic vaccines or in environmentally friendly interventions. The Animal Health IndustryAnimal health is focused on the management and control of diseases in order to ensure the health of both livestock (see Glossary) and companion animals. The global market for animal health products approaches €30 billion per year, with an annual growth rate outstripping that of human medicine. Products include biologicals (e.g., vaccines), antiparasitics/parasiticides, anti-infectives (e.g., antibiotics, antifungals), other pharmaceuticals (e.g., antihypertensives, antidiabetics), and medical feed additives (Figure 1, Key Figure). The current animal health market is understood to be driven primarily by three factors:(i) Pet owners, farmers, and veterinarians prefer more technically advanced and more convenient treatments. (ii) The growing world population increasingly demands affordable sources of protein from food animals and animal products, requiring improvements in livestock health care. (iii) The development of resistance requires new resistance-breaking preventatives and treatments.Due to the high economic impact and the immediate relevance for animal health, antiparasitics, also referred to as parasiticides, currently represent the second largest segment of the global animal health markettaking turns almost on a yearly basis with biologicals as the largest segmentaccounting for €7 billion in sales (23% of the market share) (Figures 1 and 2).In addition, animal health plays an important role in furthering the 'One Health' initiative, which is dedicated to improving the lives of all specieshuman and animalthrough the integration of human medicine, veterinary medicine, and environmental science i . The 'Antiparasitics Focus' of the Animal Health IndustryParasitic infections account for some of the most significant diseases worldwide, in both animals and humans, and are of enormous socioeconomic importance. Despite significant treatment advances in the preceding half century, they remain a major threat to livestock farming and cause large deficits for the agricultural economy. Effective parasite control is thus essential for profitability in intensive livestock production [1,2]. HighlightsAntiparasitics for the treatment of companion animals and livestock is one of the largest global market segments in the ani...

show abstract

Section: Approaches To Antiparasitic Developmentmentioning

confidence: 99%

Antiparasitics in Animal Health: Quo Vadis?

Selzer

Epe

2021

Trends in Parasitology

View full text Add to dashboard Cite

show abstract

“…A reliable vaccine is available for campylobacteriosis that can stimulate the prevention and elimination of infections in cows and bulls. The killed, whole cell vaccine available for T. foetus has not been demonstrated to stimulate immunity that consistently clears infections in bulls though vaccination of heifers and cows before the breeding season will significantly improve reproductive performance in the event of venereal transmission (Edmondson et al, 2017). For natural breeding, only virgin bulls should be introduced to cattle operations to minimize concerns regarding introduction of T. foetus or C. fetus.…”

Section: Bacterial Protozoal and Parasitic Pathogensmentioning

confidence: 99%

Review: Risks of disease transmission through semen in cattle

Givens

2018

Animal

View full text Add to dashboard Cite

The purpose of this paper is to review scientific evidence concerning pathogens that could potentially be transmitted via bovine semen. As a result of a careful analysis of the characteristics of infections that may cause transmission of disease through semen, effective control procedures can be identified that provide minimal constraint to the introduction of new bulls into herds for natural breeding and importation of valuable novel genetics through artificial insemination. The potential for transmission through bovine semen and corresponding effective control procedures are described for bovine herpesvirus 1, bovine viral diarrhea virus, bovine leukemia virus, lumpy skin disease virus, bluetongue virus, foot-and-mouth disease virus, and Schmallenberg virus. Brief consideration is also provided regarding the potential for transmission via semen of Tritrichomonas foetus, Campylobacter fetus venerealis, Brucella abortus, Leptospira spp., Histophilus somni, Ureaplasma diversum, Mycobacterium avium subsp. paratuberculosis, Chlamydiaceae, Mycobacterium bovis, Coxiella burnetii, Mycoplasma mycoides ssp. mycoides and Neospora caninum. Thoughtful and systematic control procedures can ensure the safety of introducing new bulls and cryopreserved semen into cattle production systems.

show abstract

“…This is a flagellate parasite closely related to T. vaginalis, and infects cattle. Various research reports confirm the usefulness of the vaccine against Trichomonas fetus for the protection and clearance of genital infections caused by this parasite (Chapwanya et al 2016;Edmondson et al 2017). As both of these parasites are quite similar to each other, it can also be possible to develop a vaccine for humans which can protect them against T. vaginalis infections.…”

Section: Preventive Measuresmentioning

confidence: 92%

Sexually Transmitted Parasitic Infections Both in Humans and Animals

2021

Int J Vet Sci

View full text Add to dashboard Cite

Impact of a killed Tritrichomonas foetus vaccine on clearance of the organism and subsequent fertility of heifers following experimental inoculation

Cited by 17 publications

References 11 publications

Antiparasitics in Animal Health: Quo Vadis?

Antiparasitics in Animal Health: Quo Vadis?

Review: Risks of disease transmission through semen in cattle

Sexually Transmitted Parasitic Infections Both in Humans and Animals

Contact Info

Product

Resources

About